- Home
- RVYL vs NLSP Comparison
RVYL vs NLSP Comparison
Compare RVYL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVYL
- NLSP
- Stock Information
- Founded
- RVYL 2007
- NLSP 2015
- Country
- RVYL United States
- NLSP Switzerland
- Employees
- RVYL N/A
- NLSP N/A
- Industry
- RVYL Professional Services
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- RVYL Consumer Discretionary
- NLSP Health Care
- Exchange
- RVYL Nasdaq
- NLSP Nasdaq
- Market Cap
- RVYL 5.4M
- NLSP 12.4M
- IPO Year
- RVYL N/A
- NLSP 2021
- Fundamental
- Price
- RVYL $0.64
- NLSP $2.50
- Analyst Decision
- RVYL Hold
- NLSP
- Analyst Count
- RVYL 1
- NLSP 0
- Target Price
- RVYL N/A
- NLSP N/A
- AVG Volume (30 Days)
- RVYL 24.4M
- NLSP 411.8K
- Earning Date
- RVYL 08-12-2025
- NLSP 07-15-2025
- Dividend Yield
- RVYL N/A
- NLSP N/A
- EPS Growth
- RVYL N/A
- NLSP N/A
- EPS
- RVYL N/A
- NLSP N/A
- Revenue
- RVYL $54,357,000.00
- NLSP N/A
- Revenue This Year
- RVYL $27.50
- NLSP N/A
- Revenue Next Year
- RVYL $35.71
- NLSP N/A
- P/E Ratio
- RVYL N/A
- NLSP N/A
- Revenue Growth
- RVYL N/A
- NLSP N/A
- 52 Week Low
- RVYL $0.36
- NLSP $1.30
- 52 Week High
- RVYL $2.40
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- RVYL 43.75
- NLSP 52.64
- Support Level
- RVYL $0.76
- NLSP $2.16
- Resistance Level
- RVYL $0.98
- NLSP $3.08
- Average True Range (ATR)
- RVYL 0.10
- NLSP 0.24
- MACD
- RVYL 0.00
- NLSP -0.00
- Stochastic Oscillator
- RVYL 2.94
- NLSP 30.21
About RVYL Ryvyl Inc.
Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.